Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing

Journal of Molecular Diagnostics

Volumn 19, Issue 5, 2017, Pages 801-804

  Alidousty, Christina ^a   Brandes, Danielle ^a   Heydt, Carina ^a   Wagener, Svenja ^a   Wittersheim, Maike ^a   Schäfer, Stephan C ^a   Holz, Barbara ^a   Merkelbach Bruse, Sabine ^a   Büttner, Reinhard ^a   Fassunke, Jana ^a   Schultheis, Anne M ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROPLAST DNA; CELL FREE NUCLEIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BLOOD COLLECTION TUBE; BLOOD SAMPLING; CELL FREE SYSTEM; CONTROLLED STUDY; DNA EXTRACTION; DNA MUTATIONAL ANALYSIS; GENE AMPLIFICATION; HUMAN; LIQUID BIOPSY; QUANTITATIVE ANALYSIS; SOMATIC MUTATION; VENOUS BLOOD; DEVICES; GENETIC MARKER; GENETICS; LUNG TUMOR; MUTATION; PROCEDURES; STANDARDS;

BLOOD SPECIMEN COLLECTION; CELL-FREE NUCLEIC ACIDS; DNA MUTATIONAL ANALYSIS; GENETIC MARKERS; HUMANS; LIQUID BIOPSY; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85027712845     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2017.06.004     Document Type: Article

References (12)

1. Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K.M., Peters, S., Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3 (2014), iii27–iii39.
2. Chan, B.A., Hughes, B.G., Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4 (2015), 36–54.
3. Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., Varmus, H., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2, 2005, e73.
4. Huang, L., Fu, L., Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B 5 (2015), 390–401.
5. Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F.O., Hesch, R.D., Knippers, R., DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001), 1659–1665.
6. Hashad, D., Sorour, A., Ghazal, A., Talaat, I., Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal 26 (2012), 467–472.
7. No, J.H., Kim, K., Park, K.H., Kim, Y.B., Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res 32 (2012), 3467–3471.
8. Park, J.L., Kim, H.J., Choi, B.Y., Lee, H.C., Jang, H.R., Song, K.S., Noh, S.M., Kim, S.Y., Han, D.S., Kim, Y.S., Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett 3 (2012), 921–926.
9. Salvianti, F., Pinzani, P., Verderio, P., Ciniselli, C.M., Massi, D., De Giorgi, V., Grazzini, M., Pazzagli, M., Orlando, C., Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One, 7, 2012, e49843.
10. Diaz, L.A. Jr., Bardelli, A., Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 32 (2014), 579–586.
11. Sacher, A.G., Paweletz, C., Dahlberg, S.E., Alden, R.S., O'Connell, A., Feeney, N., Mach, S.L., Janne, P.A., Oxnard, G.R., Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol 2 (2016), 1014–1022.
12. Devonshire, A.S., Whale, A.S., Gutteridge, A., Jones, G., Cowen, S., Foy, C.A., Huggett, J.F., Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406 (2014), 6499–6512.